Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 15

1.

M2 macrophages or IL-33 treatment attenuate ongoing Mycobacterium tuberculosis infection.

PiƱeros AR, Campos LW, Fonseca DM, Bertolini TB, Gembre AF, Prado RQ, Alves-Filho JC, Ramos SG, Russo M, Bonato VL.

Sci Rep. 2017 Jan 27;7:41240. doi: 10.1038/srep41240.

2.

Molecular epidemiology of Mycobacterium tuberculosis among South African gold miners.

Mathema B, Lewis JJ, Connors J, Chihota VN, Shashkina E, van der Meulen M, Graviss EA, Ha NP, Kreiswirth BN, Grant AD, Fielding KL, Dorman SE, Churchyard GJ.

Ann Am Thorac Soc. 2015 Jan;12(1):12-20. doi: 10.1513/AnnalsATS.201404-150OC.

3.

Role of protease inhibitor 9 in survival and replication of Mycobacterium tuberculosis in mononuclear phagocytes from HIV-1-infected patients.

Toossi Z, Wu M, Liu S, Hirsch CS, Walrath J, van Ham M, Silver RF.

AIDS. 2014 Mar 13;28(5):679-87. doi: 10.1097/QAD.0000000000000192.

4.

Within the Enemy's Camp: contribution of the granuloma to the dissemination, persistence and transmission of Mycobacterium tuberculosis.

Shaler CR, Horvath CN, Jeyanathan M, Xing Z.

Front Immunol. 2013 Feb 14;4:30. doi: 10.3389/fimmu.2013.00030. eCollection 2013.

5.

Occupational respiratory diseases in the South African mining industry.

Nelson G.

Glob Health Action. 2013 Jan 24;6:19520. doi: 10.3402/gha.v6i0.19520.

6.

The impact of HIV, an antiretroviral programme and tuberculosis on mortality in South African platinum miners, 1992-2010.

Lim MS, Dowdeswell RJ, Murray J, Field N, Glynn JR, Sonnenberg P.

PLoS One. 2012;7(6):e38598. doi: 10.1371/journal.pone.0038598. Epub 2012 Jun 22.

7.

Modeling the dynamic relationship between HIV and the risk of drug-resistant tuberculosis.

Sergeev R, Colijn C, Murray M, Cohen T.

Sci Transl Med. 2012 May 23;4(135):135ra67. doi: 10.1126/scitranslmed.3003815.

8.

Antiretroviral therapy and the control of HIV-associated tuberculosis. Will ART do it?

Lawn SD, Harries AD, Williams BG, Chaisson RE, Losina E, De Cock KM, Wood R.

Int J Tuberc Lung Dis. 2011 May;15(5):571-81. doi: 10.5588/ijtld.10.0483.

9.

HIV-1/mycobacterium tuberculosis coinfection immunology: how does HIV-1 exacerbate tuberculosis?

Diedrich CR, Flynn JL.

Infect Immun. 2011 Apr;79(4):1407-17. doi: 10.1128/IAI.01126-10. Epub 2011 Jan 18. Review.

10.

Novel developments in the epidemic of human immunodeficiency virus and tuberculosis coinfection.

Anandaiah A, Dheda K, Keane J, Koziel H, Moore DA, Patel NR.

Am J Respir Crit Care Med. 2011 Apr 15;183(8):987-97. doi: 10.1164/rccm.201008-1246CI. Epub 2010 Dec 22. Review.

11.

Costs and consequences of additional chest x-ray in a tuberculosis prevention program in Botswana.

Samandari T, Bishai D, Luteijn M, Mosimaneotsile B, Motsamai O, Postma M, Hubben G.

Am J Respir Crit Care Med. 2011 Apr 15;183(8):1103-11. doi: 10.1164/rccm.201004-0620OC. Epub 2010 Dec 10.

12.

Changing concepts of "latent tuberculosis infection" in patients living with HIV infection.

Lawn SD, Wood R, Wilkinson RJ.

Clin Dev Immunol. 2011;2011. pii: 980594. doi: 10.1155/2011/980594. Epub 2010 Sep 26.

13.

A trend analysis and sub-regional distribution in number of people living with HIV and dying with TB in Africa, 1991 to 2006.

Uthman OA, Yahaya I, Ashfaq K, Uthman MB.

Int J Health Geogr. 2009 Nov 24;8:65. doi: 10.1186/1476-072X-8-65.

14.

Antiretroviral therapy for control of the HIV-associated tuberculosis epidemic in resource-limited settings.

Lawn SD, Kranzer K, Wood R.

Clin Chest Med. 2009 Dec;30(4):685-99, viii. doi: 10.1016/j.ccm.2009.08.010. Review.

15.

Epidemiology of HIV-associated tuberculosis.

Lawn SD, Churchyard G.

Curr Opin HIV AIDS. 2009 Jul;4(4):325-33. doi: 10.1097/COH.0b013e32832c7d61. Review.

Supplemental Content

Support Center